New MS Drug Shows ‘Excellent Profile’ in Preclinical Tests Against Approved Therapy

Stuart SchlossmanMS Drug Therapies, MS Research Study and Reports

Akaal
Pharma, a developer of small molecule drugs for the treatment of inflammation
and autoimmune diseases including multiple sclerosis (MS), recently announced
highly positive preclinical trial results on the safety and efficacy of its
drug candidate AKP-11 when compared to Gilenya (fingolimod, FTY-720), an oral
MS drug approved by the U.S. Food and Drug Administration […]


Read on »

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews